OmniAb SPAC Presentation Deck

OMNIAB + AVISTA A COMBINATION OF TWO LEADING LIFE SCIENCES FRANCHISES OmniAb Track Record Platform People ●●● ● ● ● 55+ active global partners 250+ active discovery programs Two approved OmniAb-derived products, one BLA under FDA review with Breakthrough Therapy designation 23 clinical stage antibodies and 2 approved products BIOLOGICAL INTELLIGENCETM (BI) High-throughput screening technologies Industry's only four animal species platform (transgenic rat, mouse and chicken, and cow-derived) Scientific leadership in antibody discovery, genetic engineering, biology / ion channels and systems engineering 82 employees, including 74 in R&D Headquartered in Emeryville, CA AVISTA ● CAPITAL PARTNERS Successful track record of building sustainable growth healthcare companies over 25 years $8+ billion invested in 42 healthcare companies (1) Supported 80+ add-on acquisitions Public markets expertise: 15 IPOs in healthcare sector Significant domain knowledge with healthcare industry focus Creative and flexible investment approach $115 million of fully-committed equity financing provided to OmniAb 30 professionals, including leading healthcare industry experts Headquartered in New York, NY Source: Company materials and filings. (1) Total of $8 billion equity invested includes ~$3 billion from co-investors / co-sponsors. Total of 42 healthcare companies includes transactions at DLJMB, a predecessor firm to Avista. 4 OmniAb

View entire presentation